Diseases & Longevity · File 16

Parkinson's. The 21st century neurological pandemic — with decades-long prodromal phase.

Parkinson's disease is the second most prevalent neurodegenerative after dementia, with approximately 10 million people affected globally. Its population growth is sustained — Bloem et al. (Lancet 2021) call it the 21st century neurological pandemic. Most relevant for longevity medicine: the prodromal phase lasts 10-20 years and has clinical markers measurable before motor symptoms.

Why the prodromal phase is the longevity window

Parkinson's disease is clinically diagnosed when there is already 60-70% loss of dopaminergic neurons in substantia nigra. The motor symptom (tremor, rigidity, bradykinesia) is the tip of the iceberg — beneath are 10 to 20 years of prodromal phase with identifiable non-motor markers. That is the window where longevity medicine operates, not after clinical diagnosis.

Clinically relevant prodromal markers include: REM sleep behavior disorder (RBD) — the strongest predictor, with >80% conversion to synucleinopathy in 10-15 years — anosmia (smell loss), depression, chronic constipation, nonspecific pain, autonomic dysfunction. Braak's hypothesis postulates the pathological process starts in olfactory bulb and enteric nervous system — and migrates to CNS through the vagus. That makes the gut-brain axis a central target.

When tremor appears, 60% of dopaminergic neurons are already lost. Longevity medicine operates 20 years before — in RBD, anosmia, the gut.
People affected · 2019

The global weight, in numbers

Quantitative Parkinson's data come from GBD 2019, European cohorts (PRIPS), Honolulu-Asia Aging Study, and modern meta-analyses. The burden grows fast.

  • Global prevalence

    ~10M · 2019

    Approximately 10 million people live with Parkinson's globally. Prevalence increases exponentially with age — goes from ~0.3% in >60 to >3% in >80.
    — GBD 2019 Parkinson's Disease Collaborators

  • Population growth

    ×2 esperado 2040

    Due to population aging and possible environmental factors (pesticides, endocrine disruptors), case doubling is projected by 2040. Bloem 2021 Lancet describes it as the 21st century neurological pandemic.
    — Bloem et al., Lancet 2021

  • REM sleep behavior disorder

    >80% conversión 10–15a

    RBD — acting out dreams with vigorous movements during REM — has >80% conversion rate to synucleinopathy (Parkinson, DLB, MSA) in 10-15 years. It's the strongest prodromal predictor identified.
    — Postuma et al., Brain 2019

  • Twin risk

    ~10–15% heredabilidad

    Twin studies show relatively low heritability (~10-15%) — indicating environmental and lifestyle component is greater than genetic. That makes Parkinson's a disease with significant modifiable window.
    — Goldman et al., Mov Disord 2019

Chap. 03 · Years of life expectancy lost

Impact on quality of life and functional trajectory

Parkinson's sustainably reduces functional capacity, autonomy, and quality of life — its impact is comparable to other major chronic conditions, and its non-motor component is frequently underestimated.

  • Non-motor symptoms

    Carga frecuentemente subestimada

    Depression, anxiety, cognitive decline, sleep disturbances, dysautonomia (orthostatic hypotension, constipation, sialorrhea), and chronic pain — non-motor symptoms reduce quality of life more than tremor in many patients.
    — Schapira et al., Nat Rev Neurosci 2017

  • Associated dementia

    ~30-50% a 10 años

    Approximately 30-50% of Parkinson's patients develop dementia at 10 years from diagnosis (Parkinson's disease dementia, PDD). Connection with cognitive decline is direct — it's a cortical synucleinopathy in many cases.
    — Aarsland et al., Nat Rev Neurol 2017

  • Progressive functional loss

    Hoehn & Yahr · UPDRS

    Hoehn & Yahr and UPDRS scales quantify progressive motor, ADL, and mental deterioration. The typical patient advances stage by stage over years — structured neurological rehabilitation and exercise significantly change trajectory.
    — Goetz et al., Mov Disord 2008

  • Caregiver burden

    Sostenida y creciente

    Parkinson's generates sustained family and caregiver burden — especially affects spouses. Structured psychosocial support is integral to management, not an annex.
    — Mosley et al., Maturitas 2017

What we don't offer — and what we do

Wellness Care does not manage established Parkinson's. Levodopa, dopamine agonists, MAO-B inhibitors, and deep brain stimulation are exclusively the neurologist / movement disorders specialist's competence. What we do is what the conventional system rarely addresses: the prodromal phase and environmental and lifestyle factors.

We evaluate patients with clinical prodromal markers — RBD, anosmia, depression, chronic constipation, dysautonomia — family history, or exposure to environmental risk factors (pesticides, endocrine disruptors). The approach integrates: gut health and microbiota (gut-brain axis), systemic inflammaging, neuro-specific profile when applicable, structured neuroprotective exercise, and comorbidity management. Coordinated with neurology when indicated.

We don't promise to prevent Parkinson's. What we hold: there are 10-20 years of prodromal window with measurable markers. That figure defines the opportunity.
How we measure it

How Parkinson's risk is evaluated
at Wellness Care

Clinical prodromal markers + gut-brain axis + systemic inflammaging + structured neuroprotective exercise. In neurology coordination.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications structuring the Parkinson's conversation in longevity medicine — Lancet Seminar, RBD as predictor, non-motor symptoms, gut-brain axis.

«La enfermedad de Parkinson es la pandemia neurológica del siglo XXI — con crecimiento poblacional sostenido, fase prodrómica medible y oportunidad de intervención antes del síntoma motor.»
Lancet · 2021
Bloem et al., Lancet 2021
Lancet Seminar Parkinson's
«REM sleep behavior disorder es el predictor prodrómico más potente identificado — >80% de conversión a sinucleinopatía en 10-15 años.»
Brain · 2019
Postuma et al., Brain 2019
RBD como predictor
«El paradigma moderno del Parkinson incluye la patología sinucleinopática del sistema nervioso entérico — el eje intestino-cerebro es central, no anexo.»
Nat Rev Neurosci · 2017
Schapira et al., Nat Rev Neurosci 2017
Síntomas no motores y eje intestino-cerebro

Frequently asked questions about Parkinson's disease

The most recurrent questions about Parkinson's, prodromal markers, gut-brain axis, and why longevity medicine operates decades before the motor symptom.

01

What is REM sleep behavior disorder (RBD) and why does it matter?

RBD is a sleep disorder where normal REM muscle atonia fails, and the patient "acts out" dreams with vigorous movements:

· Punches
· Kicks
· Vocalization

It's the strongest prodromal predictor of synucleinopathy identified:

· >80% conversion to Parkinson, dementia with Lewy bodies, or multiple system atrophy
· In 10-15 years

Indication for polysomnography and structured neurological follow-up.

02

Is the gut really related to Parkinson's?

Yes.

Braak's hypothesis postulates synucleinopathic pathology starts in the enteric nervous system — and migrates to CNS through the vagus nerve.

That explains why chronic constipation is one of the earliest prodromal markers (can appear 10-20 years before tremor).

Emerging targets:

· Gut microbiome
· Intestinal inflammation

Their specific modulation is still under active investigation.

03

Does exercise really protect against Parkinson's?

Epidemiological evidence is consistent:

· Regular vigorous physical activity is associated with lower Parkinson's incidence
· In already diagnosed patients, delays motor and cognitive deterioration

Clinical trials (SPARX 2018, Park-in-Shape) have shown supervised high-intensity aerobic exercise improves:

· UPDRS scores
· Functional capacity
· Quality of life

Proposed mechanism:

· Neurotrophins — BDNF, GDNF
· Inflammaging reduction
· Improved brain vascular function

04

Do pesticides really cause Parkinson's?

Multiple meta-analyses show association between sustained occupational or environmental exposure to pesticides and higher Parkinson's incidence:

· Paraquat
· Rotenone
· Organochlorines

Causality is not established with the solidity of INTERHEART cardiovascular factors, but the association is consistent.

Other emerging environmental factors:

· Endocrine disruptors
· Organic solvents
· Heavy metals

The environmental component exceeds the genetic in many cohorts.

05

When should I consult?

A structured assessment is worthwhile if you have:

· Family history of Parkinson's
· REM sleep behavior disorder or suspicion
· Progressive anosmia without identifiable cause
· Persistent depression
· Unexplained chronic constipation
· Orthostatic hypotension
· Chronic nonspecific pain
· Sustained occupational exposure to pesticides

The assessment does not diagnose Parkinson's — that is the neurologist's competence — but identifies modifiable factors and orients follow-up.

20 years of prodromal window

When tremor appears, 60% of dopaminergic neurons are already lost. Longevity medicine operates 20 years earlier — in RBD, anosmia, the gut.

Measure prodromal markers, address the gut-brain axis, structure neuroprotective exercise, modulate inflammaging, and coordinate with neurology when indicated — that is what's missing in the conventional model.

Family history or prodromal markers?

Book a neurodegeneration risk assessment

We evaluate detailed clinical history, prodromal markers (RBD, anosmia, depression, constipation), systemic inflammatory profile, metabolic profile, gut health and microbiota. If you have subjective cognitive-motor concern or family history — this is what we do. The assessment does not replace the neurologist — it complements them.

Book neurodegeneration assessment